GlassScriptPhysician profile
Sandhya Kharbanda
NPI 1750498226
$19,345.25
in general payments reported to CMS, 2019-2025
7 companies · $5,065 in 2025
The $5,065 reported for 2025 was more than what 80% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $14K · 2025: $5,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $3,524 · Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,759.00 |
| Travel and Lodging | $3,524.00 |
| Food and Beverage | $1,062.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,064.62 | 2024 | |
| Mesoblast, INC. | $3,171.67 | 2025 | Ryoncil |
| Orchard Therapeutics North America | $2,835.21 | 2024-2025 | Lenmeldy |
| Incyte Corporation | $124.99 | 2025 | Jakafi, Niktimvo |
| Genetix Biotherapeutics INC | $116.69 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $32.07 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Kharbanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.